SUNNYVALE, Calif., June 7, 2012 /PRNewswire/-- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that outcome data on intermediate risk prostate cancer patients treated with CyberKnife® Prostate SBRT was presented at the American Urological Association Meeting (AUA) 2012 held in Atlanta, Ga. The prospective monotherapy study, titled, "Four Year Outcomes and Quality of Life Following Stereotactic Body Radiation Therapy: A Rapid, Non-Invasive Alternative for the Treatment of Intermediate-Risk Organ Confined Prostate Cancer," expands upon prior studies to further evaluate the long term efficacy and quality of life outcomes from treatment with CyberKnife stereotactic body radiation therapy (SBRT) for intermediate-risk prostate cancer patients. The study found a 91 percent biochemical control rate at four-years, which is comparable to both surgical and non-surgical treatments for intermediate risk prostate cancer patients, while demonstrating similar to improved toxicity outcomes.
The study consisted of 81 intermediate-risk organ confined prostate patients treated by Dr. Alan Katz at Winthrop University Hospital with a median follow-up of four years including 24 patients with a minimum of five years follow up. This study showcases the long term published data on the use of the non-invasive CyberKnife SBRT five day course of treatment for intermediate-risk prostate cancer. Most notably the study found a four-year relapse-free survival rate of 91 percent. Patients experienced mild toxicity with minimal impact on quality of life and immediate to rapid return to normal activity. These results further support the value of CyberKnife prostate SBRT to achieve high rates of long term disease control while sparing healthy tissue and critical nearby structures, thereby minimizing undesirable side effects typically associated with other treatment modalities and preserving patients' quality of life.
"CyberKnife prostate SBRT offers patients a short five-day, non-invasive treatment for organ confined prostate cancer," said Alan Katz, M.D., author of the study, currently a radiation oncologist at Flushing Radiation Oncology. "Based on our study results, patients with intermediate-risk prostate cancer have an option for a less invasive alternative to invasive surgery or six to eight weeks of conventionally fractionated radiation therapy, that effectively and efficiently treats their cancer, while preserving their overall quality of life."
"This study represents positive long term outcomes of CyberKnife SBRT for intermediate-risk prostate patients, further supporting the value of this patient centric technique," said Omar Dawood, M.D., M.P.H., senior vice president of global medical affairs for Accuray. "These results add to the rapidly maturing strong foundation of published clinical evidence for CyberKnife prostate SBRT and further support the need to create head to head evidence to compare outcomes of this treatment with surgery and conventionally fractionated radiation treatments as is underway in the recently launched PACE study. We look forward to the outcomes of the PACE study, which aims to build upon these results and further support CyberKnife SBRT as a potential gold standard for the treatment for patients with organ confined prostate cancer."
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies the CyberKnife and TomoTherapy Systems are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to quality of life, clinical outcomes, the anticipated benefits of the CyberKnife System, the Company's ability to continue to enhance the performance of the CyberKnife Systems, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company's reports Form 10-Q for the first, second and third quarters of fiscal 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Eaun Thomson, Ph. D.
SOURCE Accuray Incorporated